Auravax Therapeutics
AuraVax Therapeutics, Inc. is focused on developing intranasal platform technologies called NanoSTING to treat and prevent respiratory infections. Their mission is to activate the body's innate immunity to provide broad-spectrum protection against multiple respiratory pathogens, independent of the specific pathogen. They aim to improve clinical outcomes, reduce transmission, and enhance vaccine effectiveness through their innovative host-directed therapeutics and adjuvants.
Industries
Nr. of Employees
small (1-50)
Products
Intranasal STING-agonist nanoparticle therapeutic (host-directed)
An intranasally administered nanoparticle formulation that delivers a STING pathway activator to boost innate immunity for prevention and early treatment of respiratory infections independent of pathogen identity.
STING-agonist mucosal adjuvant for intranasal vaccines
A mucosal adjuvant formulation intended to be combined with intranasal vaccines to enhance mucosal and systemic immunity and enable needle-free vaccine delivery.
Platform licensing for intranasal STING-based products
Licensing of the intranasal STING-agonist nanoparticle platform to collaborators for development of therapeutics and vaccine adjuvants.
NanoSTING-001
A host-directed broad antiviral therapeutic operating in the nose to reduce viral load, act as an immunological shield, and decrease transmission between individuals.
NanoSTING-002
An adjuvant and combination therapeutic designed to be paired with current and future vaccines to enable needle-free nasal delivery and provide a comprehensive immune response.
NanoSTING-003
A next generation host-directed therapeutic being developed by AuraVax.
Intranasal STING-agonist nanoparticle therapeutic (host-directed)
An intranasally administered nanoparticle formulation that delivers a STING pathway activator to boost innate immunity for prevention and early treatment of respiratory infections independent of pathogen identity.
STING-agonist mucosal adjuvant for intranasal vaccines
A mucosal adjuvant formulation intended to be combined with intranasal vaccines to enhance mucosal and systemic immunity and enable needle-free vaccine delivery.
Platform licensing for intranasal STING-based products
Licensing of the intranasal STING-agonist nanoparticle platform to collaborators for development of therapeutics and vaccine adjuvants.
NanoSTING-001
A host-directed broad antiviral therapeutic operating in the nose to reduce viral load, act as an immunological shield, and decrease transmission between individuals.
NanoSTING-002
An adjuvant and combination therapeutic designed to be paired with current and future vaccines to enable needle-free nasal delivery and provide a comprehensive immune response.
NanoSTING-003
A next generation host-directed therapeutic being developed by AuraVax.
Services
In vivo efficacy and safety studies, immunological and virological assay support, and preclinical data generation to advance intranasal host-directed therapeutics and intranasal vaccine adjuvants.
Negotiation and execution of exclusive licenses with academic institutions and participation in government-funded evaluation contracts to advance platform development.
In vivo efficacy and safety studies, immunological and virological assay support, and preclinical data generation to advance intranasal host-directed therapeutics and intranasal vaccine adjuvants.
Negotiation and execution of exclusive licenses with academic institutions and participation in government-funded evaluation contracts to advance platform development.
Expertise Areas
- Host-directed therapeutics for respiratory disease
- Mucosal vaccine adjuvant development
- Intranasal drug formulation and delivery
- Preclinical animal models and translational immunology
Key Technologies
- STING pathway activation (cGAMP delivery)
- Liposomal / lipid nanoparticle carriers
- Intranasal (mucosal) delivery
- Mucosal adjuvantation
News & Updates
A publication about a nasal vaccine developed by the University of Houston that prevents COVID-19 from spreading.
A press release about AuraVax receiving a contract from BARDA to evaluate NanoSTING as an adjuvant for intranasal influenza vaccines.
A scientific publication about a multi-antigen intranasal vaccine that protects against sarbecoviruses and prevents transmission in animal models.
A scientific publication about an intranasal nanoparticle STING agonist that offers protection against respiratory viruses in animal studies.
A publication about the effectiveness of a nasal vaccine candidate in preventing COVID-19 transmission.
A publication about a nasal vaccine developed by the University of Houston that prevents COVID-19 from spreading.
A press release about AuraVax receiving a contract from BARDA to evaluate NanoSTING as an adjuvant for intranasal influenza vaccines.
A scientific publication about a multi-antigen intranasal vaccine that protects against sarbecoviruses and prevents transmission in animal models.
A scientific publication about an intranasal nanoparticle STING agonist that offers protection against respiratory viruses in animal studies.
A publication about the effectiveness of a nasal vaccine candidate in preventing COVID-19 transmission.